Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia

被引:135
作者
Morris, A
Wachter, RM
Luce, J
Turner, J
Huang, L
机构
[1] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA
[2] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
关键词
AIDS; intensive care; antiretroviral therapy; Pneumocystis carinii; opportunistic infections; combination therapy;
D O I
10.1097/00002030-200301030-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Although the incidence of Pneumocystis carinii pneumonia (PCP) has declined, mortality of patients who require intensive care for this disease remains high. Highly active antiretroviral therapy, (HAART) might alter the course of PCP either via effects on the immune system or through anti-Pneumocystis actions; however, HAART has not been studied in patients acutely ill with PCP. Objective: To assess the effects of HAART on outcome of patients admitted to the intensive care unit (ICU) with PCP. Design and setting: Retrospective cohort study carried out at a University-affiliated county hospital. Participants: Fifty-eight HIV-infected adults with PCP admitted to an ICU from 1996 to 2001. Measurements: A standardized chart review was performed to collect information on demographic variables, hospital course, and use of antiretroviral therapy. Outcome measured was death while in the ICU or hospital. Results: A total of 20.7% of patients were either receiving HAART or were started on therapy while hospitalized. Mortality in this group was 25%, whereas mortality in those not receiving therapy was 63% (P=0.03). Multiple logistic regression analyses adjusting for potential confounders showed that HAART started either before or during hospitalization was associated with a lower mortality [odds ratio (OR), 0.14; 95% confidence interval (95% CI), 0.02-0.84; P=0.03). The need for mechanical ventilation and/or development of a pneumothorax (OR, 20.9; 95% CI, 1.9-22 7.2; P = 0.01) and delayed ICU admission (OR, 9.7; 95% CI, 2.2-42.1; P=0.002) were associated with increased mortality. Conclusions: Use of HAART is an independent predictor of decreased mortality in severe PCP and may represent a potential therapy to improve outcome in this disease. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 31 条
[1]   Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU - The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study [J].
Afessa, B ;
Green, B .
CHEST, 2000, 118 (01) :138-145
[2]   Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients [J].
Alves, C ;
Nicolás, JM ;
Miró, JM ;
Torres, A ;
Agustì, C ;
Gonzalez, J ;
Rañó, A ;
Benito, N ;
Moreno, A ;
Garcìa, F ;
Millá, J ;
Gatell, JM .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (01) :87-93
[3]   In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii [J].
Atzori, C ;
Angeli, E ;
Mainini, A ;
Agostoni, F ;
Micheli, V ;
Cargnel, A .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1629-1634
[4]   Pneumocystis carinii pneumonia requiring intensive care management:: Survival and prognostic study in 110 patients with human immunodeficiency virus [J].
Bédos, JP ;
Dumoulin, JL ;
Gachot, B ;
Veber, B ;
Wolff, M ;
Régnier, B ;
Chevret, S .
CRITICAL CARE MEDICINE, 1999, 27 (06) :1109-1115
[5]   A CONTROLLED TRIAL OF EARLY ADJUNCTIVE TREATMENT WITH CORTICOSTEROIDS FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
BOZZETTE, SA ;
SATTLER, FR ;
CHIU, J ;
WU, AW ;
GLUCKSTEIN, D ;
KEMPER, C ;
BARTOK, A ;
NIOSI, J ;
ABRAMSON, I ;
COFFMAN, J ;
HUGHLETT, C ;
LOYA, R ;
CASSENS, B ;
AKIL, B ;
MENG, TC ;
BOYLEN, CT ;
NIELSEN, D ;
RICHMAN, DD ;
TILLES, JG ;
LEEDOM, J ;
MCCUTCHAN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (21) :1451-1457
[6]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[7]  
Curtis JR, 2000, AM J RESP CRIT CARE, V162, P393, DOI 10.1164/ajrccm.162.2.9909014
[8]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[9]   CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy [J].
Deeks, SG ;
Hoh, R ;
Grant, RM ;
Wrin, T ;
Barbour, JD ;
Narvaez, A ;
Cesar, D ;
Abe, K ;
Hanley, MB ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (03) :315-323
[10]   OUTCOME OF INTENSIVE-CARE IN PATIENTS WITH HIV-INFECTION [J].
DEPALO, VA ;
MILLSTEIN, BH ;
MAYO, PH ;
SALZMAN, SH ;
ROSEN, MJ .
CHEST, 1995, 107 (02) :506-510